exendin (9-39)

a peptide from the venom of the lizard Heloderma suspectum; inhibits glucagon-like peptide-1 (GLP-1) induced cAMP production; its structure is related to exendin-4

Also Known As:

exendin (9-39) amide; exendin(9-39)amide; exendin-(9-39); Exendin 3 (Heloderma horridum), 1-de-L-histidine-2-de-L-serine-3-de-L-aspartic acid-4-deglycine-5-de-L-threonine-6-de-L-phenylalanine-7-de-L-threonine-8-de-L-serine-

Networked: 53 relevant articles (4 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Peptide Fragments: 373
    - exendin (9-39): 53

Experts

1.	Rudd, John A: 5 articles (12/2020 - 07/2013)
2.	De León, Diva D: 4 articles (01/2022 - 09/2008)
3.	Lu, Zengbing: 4 articles (12/2020 - 08/2014)
4.	Lin, Ge: 4 articles (11/2017 - 07/2013)
5.	Chan, Sze Wa: 3 articles (12/2020 - 07/2013)
6.	Yew, David T W: 2 articles (11/2017 - 01/2017)
7.	Ocampo-García, Blanca E: 2 articles (11/2017 - 12/2015)
8.	Santos-Cuevas, Clara L: 2 articles (11/2017 - 12/2015)
9.	Jiménez, Amanda: 2 articles (07/2016 - 10/2014)
10.	Vidal, Josep: 2 articles (07/2016 - 10/2014)

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 01/01/2022 - "In comparison with vehicle, infusion of exendin-(9-39) resulted in significant reduction in likelihood of hypoglycemia in group 2, by 76% (P = 0.009), and in group 3, by 84% (P = 0.014). " 01/01/2022 - "Administration of exendin-(9-39) during the OPTT resulted in 82% (P = 0.007) reduction in the likelihood of hypoglycemia. " 09/19/2008 - "Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion." 10/01/2012 - "In preclinical studies, we showed that the GLP-1 receptor antagonist exendin-(9-39) suppresses insulin secretion and corrects fasting hypoglycemia in SUR-1(-/-) mice. " 01/01/2022 - "These results support a therapeutic potential of exendin-(9-39) to prevent fasting and protein-induced hypoglycemia in children with HI."
2.	Weight Loss (Weight Reduction) 07/01/2016 - "Studies in humans using the specific GLP-1 receptor antagonist exendin 9-39 or the nonspecific inhibitor of GLP-1 secretion octreotide, as well as data derived from genetically engineered mouse models, provide strong evidence that although GLP-1 retains its physiologic role, it is not the cause of the amelioration of glucose tolerance or sustained weight loss after Roux-en-Y gastric bypass or sleeve gastrectomy. " 02/01/2015 - "glucagon-like peptide-1 (GLP-1), peptide YY].Improved glucose metabolism after RYGB and sleeve gastrectomy involves several mechanisms: early increased hepatic insulin sensitivity, resulting from reduced liver fat content in response to the postoperative caloric restriction, improved beta-cell function mediated by exaggerated postprandial GLP-1 secretion; as demonstrated by relapse of impaired glucose tolerance in studies blocking the GLP-1 receptor by exendin 9-39, and later after major weight loss increased peripheral insulin sensitivity. "
3.	Insulin Resistance 09/19/2008 - "Exendin-(9-39) did not further worsen glucose tolerance and had no effect on body weight and insulin sensitivity. " 02/01/2015 - "glucagon-like peptide-1 (GLP-1), peptide YY].Improved glucose metabolism after RYGB and sleeve gastrectomy involves several mechanisms: early increased hepatic insulin sensitivity, resulting from reduced liver fat content in response to the postoperative caloric restriction, improved beta-cell function mediated by exaggerated postprandial GLP-1 secretion; as demonstrated by relapse of impaired glucose tolerance in studies blocking the GLP-1 receptor by exendin 9-39, and later after major weight loss increased peripheral insulin sensitivity. "
4.	Type 2 Diabetes Mellitus (MODY) 01/01/2016 - "Vildagliptin significantly increased this ratio by 10.5% in patients with type 2 diabetes, and exendin [9-39] reduced it (both P < 0.0001). " 10/01/2014 - "To better understand the role of GLP-1 in the remission of type 2 diabetes mellitus (T2DM) long term after SG in humans, we conducted two separate cross-sectional studies: 1) the GLP-1 response to a standardized mixed liquid meal (SMLM) was compared in subjects with T2DM antedating SG but with different long-term (>2 years) T2DM outcomes (remission, relapse, or lack of remission) (study 1) and 2) the effect of GLP-1 receptor blockade with exendin (9-39) on glucose tolerance was examined in subjects with T2DM antedating surgery, who had undergone SG and presented with long-term T2DM remission (study 2). " 01/01/2016 - "Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist." 01/01/2016 - "We quantified the contribution of GLP-1 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin) by using the GLP-1 receptor antagonist exendin [9-39] in patients with type 2 diabetes and in healthy subjects. "
5.	Glucose Intolerance 02/01/2015 - "glucagon-like peptide-1 (GLP-1), peptide YY].Improved glucose metabolism after RYGB and sleeve gastrectomy involves several mechanisms: early increased hepatic insulin sensitivity, resulting from reduced liver fat content in response to the postoperative caloric restriction, improved beta-cell function mediated by exaggerated postprandial GLP-1 secretion; as demonstrated by relapse of impaired glucose tolerance in studies blocking the GLP-1 receptor by exendin 9-39, and later after major weight loss increased peripheral insulin sensitivity. "

Related Drugs and Biologics

1.	Glucagon-Like Peptide-1 Receptor
2.	Glucose (Dextrose)
3.	Glucagon-Like Peptide 1 (GLP 1)
4.	Peptide YY
5.	Insulin (Novolin)
6.	Blood Glucose (Blood Sugar)
7.	Exenatide (Byetta)
8.	Cisplatin (Platino)
9.	Octreotide (Sandostatin)
10.	Streptozocin (Streptozotocin)

Related Therapies and Procedures

1.	Gastrectomy
2.	Caloric Restriction
3.	Gastric Bypass (Roux-en-Y Gastric Bypass)
4.	Injections
5.	Intravenous Administration